

# Synthesis and Biological Evaluation of $\beta$ -Aroylpropionic acid based 1,3,4-Oxadiazoles

A. HUSAIN\*, PRIYANKA AHUJA AND SARAFROZ

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi-110 062, India

Husain *et al.*: Synthesis and biological evaluation of 1,3,4-oxadiazoles

In the present investigation, two new series, 1-(4-benzylphenyl)-3-(5-substituted-1,3,4-oxadiazol-2-yl)-1-propanone and 1-(4-ethylphenyl)-3-(5-substituted-1,3,4-oxadiazol-2-yl)-1-propanone from  $\beta$ -(4-benzylbenzoyl)propionic acid and  $\beta$ -(4-ethylbenzoyl)propionic acid, respectively, were synthesized and tested for antiinflammatory, analgesic, lipid peroxidation, ulcerogenic and antibacterial actions. A fair number of compounds were found to have good antiinflammatory activity in carrageenan-induced rat paw edema test, while a few compounds showed significant antibacterial activity. The newly synthesized compounds showed very low ulcerogenic action.

Key words: Oxadiazoles, aroylpropionic acid, antiinflammatory, analgesic, antibacterial

---

\*Address for correspondence

E-mail: drasifhusain@yahoo.com


A diversity of useful biological effects is possessed by heterocyclic compounds containing the five-membered oxadiazole nucleus<sup>[1]</sup>. In particular, compounds bearing 1,3,4-oxadiazole nucleus are known to exhibit unique antiedema and antiinflammatory activity<sup>[2-5]</sup>. Differently substituted oxadiazole moiety has also been found to have other interesting activities such as analgesic<sup>[3,4]</sup>, antimicrobial<sup>[6,7]</sup>, antitubercular<sup>[8]</sup>, anticonvulsant<sup>[9]</sup> and antitumor activities<sup>[5]</sup>. The most prevalent side effects of commonly used NSAIDs are the occurrence of gastrointestinal damage with gastric upset and irritation. Studies suggest that the direct tissue contact of these agents plays an important role in the production of gastric side effects<sup>[10,11]</sup>. Aroylpropionic acids are good antiinflammatory agents but produce gastrointestinal side effects and these side effects are due to presence of free carboxylic group in the molecule<sup>[12,13]</sup>. Therefore, it was considered worthwhile to synthesize some new  $\beta$ -aroylpropionic acid derivatives by converting the free terminal carboxylic group into oxadiazolyl moiety with the hope to get better molecules.

As shown in Scheme 1, The starting materials,  $\beta$ -(4-benzylbenzoyl)propionic acid 3 and  $\beta$ -(4-ethylbenzoyl)propionic acid 4, were prepared by condensing diphenylmethane or ethylbenzene with succinic

anhydride in presence of anhydrous aluminium chloride following Friedel-Craft's acylation reaction conditions. Reaction between  $\beta$ -(4-benzylbenzoyl)propionic acid 3 or  $\beta$ -(4-ethylbenzoyl)propionic acid 4 with aryl acid hydrazides 2a-l in phosphorous oxychloride (reaction time varies from 2 to 5 h) afforded title compounds 5a-l and 6a-e. Both analytical and spectral data [<sup>1</sup>H NMR, Mass (HREIMS) and IR] of the synthesized compounds are in agreement with the proposed structures.

Melting points were determined with the help of open glass capillaries using Kjeldahl flask containing liquid paraffin and are uncorrected. Purity of the compounds was checked by TLC on silica gel plates and spots were visualized by exposure to iodine vapors. <sup>1</sup>H NMR spectra were recorded on Varian E-360 MHz or Bruker spectropsin DPX-300MHz with tetramethylsilane as internal standard in solvent CDCl<sub>3</sub>. The IR spectra were recorded on a Perkin-Elmer 1600 FTIR spectrophotometer in potassium bromide pellets. Mass spectra were recorded on a Jeol JMS-D 300 instrument fitted with a JMS 2000 data system at 70 eV.

Ethyl esters of aromatic acids (1a-l) and aryl acid hydrazides (2a-l) were synthesized according to the literature method<sup>[14]</sup>.



Scheme 1: Synthetic route for the preparation of 1,3,4-oxadiazoles, 5a-l, 6a-e

Aryl hydrazide 2a (1 mol) was dissolved in phosphorous oxychloride (5 ml) and to it was added compound 3 (equimolar; 1 mmol). The reaction mixture, after refluxing for 4h, was cooled to room temperature and poured onto crushed ice. On neutralization of the contents with sodium bicarbonate solution (20%), a solid mass separated out, which was filtered and washed with water. It was crystallized from methanol to give 5a. Similarly 5b-l and 6a-e were prepared (Table 1).

In general, IR spectral data ( $\text{cm}^{-1}$ ) of the compounds revealed bands at 3100-3030 (C-H); 1665-1650 (C=O); 1440-1420 (C-N) and 810-750 (aromatic) and 830-815 (*p*-disubstituted).  $^1\text{H-NMR}$  spectral studies of the title compounds showed two triplets of two protons each at around  $\delta$  2.6 and  $\delta$  3.5 which could be assigned to two methylene protons ( $-\text{CH}_2-\text{CH}_2-$ ). A signal was observed at around  $\delta$  4.02 in case of compounds 5a-l, which could be accounted for the methylene group ( $-\text{CH}_2-$ ) present between two phenyl rings. There appeared signals (triplet at around  $\delta$  1.26 for  $\text{CH}_3\text{CH}_2-$  and quartet at around  $\delta$  2.69 for  $\text{CH}_3\text{CH}_2-$ ), for ethyl function in case of compounds 6a-e. Aromatic protons appeared in the region 7.03-8.06 ppm. Other peaks were observed at appropriate places. The mass spectra showed acylium fragments containing benzylphenyl/ethylphenyl and aryl moieties as major peaks followed by peaks with loss of CO besides the molecular ion peaks in reasonable intensities supporting the structure.

Antiinflammatory activity of the compounds was

evaluated by carrageenan-induced paw edema test in rats<sup>[15]</sup>, at a dose of 20 mg/kg *po*, using indomethacin as standard drug at same dose level. Swiss rats of either sex (150-200 g) were divided into control, standard, and test groups, each comprising of six rats. The protocol of animal experiments has been approved by the Institutional Animal Ethics Committee (IAEC). Freshly prepared suspension of carrageenan (0.05 ml, 1% w/v solution in 0.9% saline) was injected under the planter aponeurosis of the left hind paw of each rat. One group was kept as control and the animals of other groups were pre-treated with the test drugs suspended in 1% carboxymethylcellulose (CMC) given orally 30 min before carrageenan injection. The foot volume was measured using the mercury displacement technique, with the help of plethysmograph, both in control as well as test animals including standard drug animals, before and after 3 h of carrageenan injection. The percentage inhibition of inflammation was calculated using the formula, % inhibition =  $(1 - \text{Vt}/\text{Vc}) \times 100$ , where, Vt and Vc are the mean relative changes in the volume of paw edema in the test and control, respectively. The results are summarised in Table 2.

Analgesic activity was carried out by acetic acid induced writhing method<sup>[16]</sup> using albino mice (25-30 g) of either sex on groups of six animals each. A 1% aqueous acetic acid solution (i.p. injection; 0.1 ml) was used as writhing induced agent. Mice were kept individually in the test cage, before acetic acid injection and habituated for 30 min. Screening of analgesic activity was performed after

**TABLE 1: PHYSICAL CONSTANTS OF THE TITLE COMPOUNDS**

Compound	R	MP (O)	Yield (%)	Molecular formula	Molecularweight
3	-	178-180	48	$\text{C}_{17}\text{H}_{16}\text{O}_3$	268.31
4	-	110	64	$\text{C}_{12}\text{H}_{14}\text{O}_3$	206.24
5a	$\text{C}_6\text{H}_5$	154	52	$\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_2$	368.43
5b	3- $\text{NO}_2-\text{C}_6\text{H}_4$	178-180	56	$\text{C}_{24}\text{H}_{19}\text{N}_3\text{O}_4$	413.43
5c	4- $\text{F}-\text{C}_6\text{H}_4$	142-144	54	$\text{C}_{24}\text{H}_{19}\text{FN}_2\text{O}_2$	386.42
5d	4- $\text{OCH}_3-\text{C}_6\text{H}_4$	172-174	63	$\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_3$	398.46
5e	$\text{C}_6\text{H}_5-\text{COC}_6\text{H}_4$	188	58	$\text{C}_{31}\text{H}_{24}\text{N}_2\text{O}_3$	472.54
5f	2- $\text{Cl}-\text{C}_6\text{H}_4$	160-162	56	$\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_2$	402.88
5g	4- $\text{Cl}-\text{C}_6\text{H}_4$	172-174	66	$\text{C}_{24}\text{H}_{19}\text{ClN}_2\text{O}_2$	402.88
5h	3,4- $(\text{OCH}_3)_2-\text{C}_6\text{H}_3$	166-168	59	$\text{C}_{26}\text{H}_{24}\text{N}_2\text{O}_4$	428.48
5i	$\text{C}_6\text{H}_5-\text{CH}_2$	154	63	$\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_2$	382.46
5j	$\text{C}_6\text{H}_5-\text{OCH}_2$	166	54	$\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_3$	398.46
5k	1- $\text{C}_{10}\text{H}_7-\text{OCH}_2$	170-172	52	$\text{C}_{29}\text{H}_{24}\text{N}_2\text{O}_3$	448.52
5l	2- $\text{C}_{10}\text{H}_7-\text{OCH}_2$	190-192	50	$\text{C}_{29}\text{H}_{24}\text{N}_2\text{O}_3$	448.52
6a	$\text{C}_6\text{H}_5$	122-124	62	$\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2$	306.36
6b	3- $\text{NO}_2-\text{C}_6\text{H}_4$	128-130	60	$\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_4$	351.36
6c	4- $\text{F}-\text{C}_6\text{H}_4$	116-118	55	$\text{C}_{19}\text{H}_{17}\text{FN}_2\text{O}_2$	324.35
6d	4- $\text{OCH}_3-\text{C}_6\text{H}_4$	134-136	63	$\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_3$	336.38
6e	$\text{C}_6\text{H}_5-\text{COC}_6\text{H}_4$	154-156	57	$\text{C}_{26}\text{H}_{22}\text{N}_2\text{O}_3$	410.47

All the compounds were recrystallized from methanol.

oral administration of test drugs at the dose of 20 mg/kg. All compounds were dissolved in 1% carboxymethylcellulose (CMC) solution. One group was kept for the control experiment and received *po* administration of 1% CMC. Aspirin was used as standard at the dose of 100 mg/kg *po*. After 1 h of drug administration 0.10 ml of 1% acetic acid solution was given to mice intraperitoneally. Stretching movements consisting of arching of the back, elongation of body and extension of hind limbs were counted for 5-15 min of acetic acid injection. The analgesic activity was expressed in terms of % protection. % Analgesic activity =  $(n - n'/n) \times 100$  where  $n$  = mean number of writhes of control group and  $n'$  = mean number of writhes of test group. The percent protection in mice brought about by administration of the drugs is shown in Table 2.

Acute ulcerogenesis test was done according to Cioli *et al*<sup>[11]</sup>. Albino rats (150-200 g) were divided into different groups consisting of six animals in each group. Ulcerogenic activity was evaluated after oral administration of test compounds or indomethacin at the dose of 60 mg/kg. Control rats received oral administration of vehicle (suspension of 1% methylcellulose). Food but not water was removed 24 h before administration of the test compounds. After the drug treatment, the rats were fed normal diet for 17 h and then sacrificed. The stomach was removed and opened along the greater curvature, washed with distilled water and cleaned gently by

dipping in saline. The gastric mucosa of the rats was examined by means of a magnifying glass. For each stomach, the severity of mucosal damage was assessed according to the following scoring system: 0.5- redness; 1.0- spot ulcers; 1.5- hemorrhagic streaks; 2.0- ulcers <3, but ≤5; 3.0- ulcers >5. The mean score of each treated group minus the mean score of the control group was considered as severity index of gastric mucosal damage.

Antibacterial activity of newly synthesized compounds was determined against the bacterial strains gram positive (*Staphylococcus aureus*; NCTC-6571) and gram negative (*Escherichia coli*; ATCC-25922). The test was carried out according to the turbidity method<sup>[17]</sup>. A solution of the compounds was prepared in dimethylformamide (DMF) and a series of doubling dilutions prepared with sterile pipettes. To each of a series of sterile stoppered test tubes a standard volume of nutrient broth medium was added. A control tube containing no antimicrobial agent was included. The inoculum consisting of an overnight broth culture of microorganisms was added to separate tubes. The tubes were incubated at 37° for 24 h and examined for turbidity. The tube with highest dilution showing no turbidity was MIC. Nitrofurazone was used as standard drug.

The antiinflammatory activity (Table 2), revealed that the compounds 5d and 5h showed very good antiinflammatory activity (52.60 and 56.20%

**TABLE 2: RESULTS OF ANTIINFLAMMATORY, ANALGESIC, ULCEROGENIC AND ANTIBACTERIAL ACTIVITIES**

Compound	Antiinflammatory activity* (% inhibition ± SEM)	Analgesic activity* (% protection ± SEM)	Ulcerogenic activity* (severity index)	Antimicrobial activity (MIC; µg/ml)	
5a	25.92±1.04	32.44±0.84	0.416	-	-
5b	19.40±1.60	24.42±0.98	0.750	>100	-
5c	33.33±1.07	19.08±0.65	0.833	50	>100
5d	52.60±0.59	40.07±0.90	0.666	>100	>100
5e	29.63±1.18	32.44±1.13	0.583	-	-
5f	36.36±1.38	51.31±0.42	0.916	>100	>100
5g	46.00±1.16	45.80±0.29	1.083	25	50
5h	56.20±2.32	54.12±0.62	0.333	-	-
5i	13.64±1.06	19.08±1.33	0.583	-	-
5j	19.35±2.20	14.33±1.50	0.666	-	>100
5k	35.60±1.28	19.08±0.65	0.833	-	-
5l	29.63±1.33	26.42±1.44	0.583	-	-
6a	25.92±2.83	24.42±1.50	0.916	-	-
6b	13.00±3.61	19.08±0.66	1.083	-	-
6c	29.63±1.54	26.42±1.44	0.833	50	>100
6d	35.60±1.96	45.12±0.11	0.750	-	-
6e	32.33±1.65	29.17±1.18	0.333	-	-
Indomethacin	64.25±2.03	nt	2.666	-	-
Aspirin	nt	61.86±0.22	nt	-	-
Nitrofurazone	-	-	-	12.5	6.5

\*Number of animal used in each group is 6. 'nt' indicates not tested. '-' indicates insignificant antimicrobial activity. SEM indicates standard error of the mean and MIC is minimum inhibitory concentration.

inhibition, respectively), which was comparable to that of indomethacin (64.25% inhibition). Amongst the compounds subjected to analgesic activity (Table 2), compounds 5f and 5h were found to possess significant activity (51.31 and 54.12% protection, respectively), while the standard drug aspirin showed 61.86% activity. All the synthesized compounds showed very low ulcerogenic activity (0.416-1.083 severity index), whereas the standard drug indomethacin showed high severity index of 2.666 (Table 2). The results indicate that the compounds are almost devoid of ulcerogenic action. From the antibacterial results (Table 2), it was observed that the compound 5g was the most active among the tested compounds with MIC- 25 µg/ml against *S. aureus* and MIC- 50 µg/ml against *E. coli*. The rest of the compounds were moderate or inactive in their action.

## ACKNOWLEDGEMENTS

Financial support provided by the DST, New Delhi, under SERC-fast track scheme is gratefully acknowledged. Thanks are due to Ranbaxy Research Laboratories for providing spectral data of the compounds. We are also thankful to Mrs. Shaukat Shah, In-charge animal house, for providing animals for pharmacological studies and Prof. (Mrs.) P. K. Pillai for helping in carrying out antimicrobial activity of the compounds.

## REFERENCES

1. Franski R. Biological activities of the compounds bearing 1,3,4-oxa(thia)diazole ring. *Asian J Chem* 2005;17:2063-75.
2. Omar FA, Mahfouz NM, Rahman MA. Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives. *Eur J Med Chem* 1996;31:819-25.
3. Narayana B, Vijayaraj KK, Ashalatha BV, Kumari NS. Synthesis of some new 2-(6-methoxy-2-naphthyl)-5-aryl-1,3,4-oxadiazoles as possible non-steroidal antiinflammatory and analgesic agents. *Arch Pharm (Weinheim)* 2005;338:373-7.
4. Kamble RR, Sudha BS. Synthesis and Pharmacological Screening of 5-methyl-3-[p-(6'-aryl-2'-thioxo-1',2',5',6'-tetrahydropyrimidin-4'-yl)-phenyl]-3H-2-oxo- $\Delta^4$ -1,3,4-oxadiazoles. *Indian J Pharm Sci* 2006;68:249-53.
5. Bezerra NMM, De Oliveira SP, Srivastava RM, Da Silva JR. Synthesis of 3-aryl-5-decapentyl-1,2,4-oxadiazoles possessing antiinflammatory and antitumor properties. *Farmaco* 2005;60:955-60.
6. Gaonkar SL, Rai KM, Prabhuswamy B. Synthesis and antimicrobial studies of a new series of 2-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]-5-substituted-1,3,4-oxadiazoles. *Eur J Med Chem* 2006;41:841-6.
7. Mishra P, Rajak H, Mehta A. Synthesis of Schiff bases of 2-amino-5-aryl-1,3,4-oxadiazoles and their evaluation for antimicrobial activities. *J Gen Appl Microbiol* 2005;51:133-41.
8. Ali MA, Yar MS. Oxadiazole Mannich bases: Synthesis and antimycobacterial activity. *Bioorg Med Chem Lett* 2007;17:3314-6.
9. Zarghi A, Tabatabai SA, Faizi M, Ahadian A, Navabi P, Zanganeh V, *et al.* Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazole. *Bioorg Med Chem Lett* 2005;15:1863-5.
10. Tan TM, Chen Y, Kong KH, Bai J, Li Y, Lim SG, *et al.* NSAID, ulcer and prostaglandins. *J Rheumatol* 1992;19:68-73.
11. Cioli V, Putzolu S, Rossi V, Barcellona PS, Corradino C. The role of direct tissue contact in the production of gastro-intestinal ulcer by antiinflammatory drugs in rats. *Toxicol Appl Pharmacol* 1979;50:283-9.
12. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. *Am J Gastroenterol* 1998;93:2037-46.
13. Testa B, Jenner P. *Drug Metabolism, Chemical and Biochemical Aspect*, New York: Marcel Dekker Inc.; 1976. p. 138.
14. Furniss B, Hannaford AH, Smith PW, Tatchell AR. editors. *Vogel's Text book of Practical Organic Chemistry*, 5th ed. London: Prentice Hall; 1998. p. 1077.
15. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. *Proc Soc Exp Biol Med* 1962;111:544-7.
16. Siegmund E, Cadmus R, Lu G. A method for evaluating both non-narcotic and narcotic analgesics. *Proc Soc Exp Biol* 1957;95:729-31.
17. Barry A, In; Lorian V. editors. *Antibiotics in laboratory medicine*. Baltimore: The Williams & Wilkins Co; 1991. p. 01.

Accepted 27 January, 2009

Revised 12 July 2008

Received 01 February 2008

Indian J. Pharm. Sci., 2009, 71 (1): 62-66